GLPwatch

GLP-1 receptor agonist exendin-4 suppresses food intake by inhibiting hindbrain orexigenic NPY neurons.

Am J Physiol Endocrinol Metab · 2025

Last updated 2026-05-28

In a lab study, researchers found that the GLP-1 drug exendin-4 reduces food intake by indirectly blocking the activity of orexigenic (appetite-stimulating) neurons in the brainstem. These neurons, called NPY neurons, normally increase hunger, but exendin-4 inhibits them by boosting signals that suppress their activity. When these neurons were artificially activated, they counteracted the drug’s ability to reduce eating, while inhibiting them mimicked the drug’s effects.

AI summary of the abstract below.

JournalAm J Physiol Endocrinol Metab, 2025
Citations1
Molecules
Conditions studied Obesity

Abstract

Peripherally delivered glucagon-like peptide-1 (GLP-1)-based drugs suppress eating through their action in the brain. However, the specific neuronal mechanisms, especially their impacts on the orexigenic circuit, remain largely elusive. Neuropeptide Y (NPY) neurons in the nucleus tractus solitarius (NTS) are newly identified as orexigenic neurons with a potent eating-stimulating effect, but their responses to GLP-1 drugs are unknown. Through ex vivo electrophysiological recordings, we study the impacts of GLP-1 receptor (GLP-1R) agonist exendin-4 on NTS neurons. We discovered that the GLP-1R agonist exendin-4 inhibits NTS neuronal activity via GABA receptors by augmenting presynaptic GABA release. We also explored the contribution of NTS neurons to exendin-4-mediated eating suppression. Interestingly, chemogenetic activation of NTS neurons effectively counteracted exendin-4-induced anorexigenic effect. Moreover, chemogenetic inhibition of NTS neurons mimicked the eating-suppressing effect of exendin-4. Collectively, our findings highlight a population of orexigenic NTS neurons that may be targeted by a GLP-1R agonist to suppress food intake, suggesting that this neuronal population has translational importance as a potential therapeutic target for obesity treatment. This study discovers that the glucagon-like peptide-1 (GLP-1) receptor agonist exendin-4 indirectly inhibits the majority of orexigenic hindbrain NPY neurons via GABA receptors by augmenting presynaptic GABA release. Chemogenetic activation of these NPY neurons effectively counteracts exendin-4 (Exn-4)-induced anorexigenic effect, whereas chemogenetic inhibition of them mimics the eating-suppressing effect of exendin-4. This study uncovers a mechanism by which Exn-4 inhibits orexigenic hindbrain NPY neurons, thereby providing new insights into how GLP-1 drugs suppress food intake.

Verbatim abstract via PubMed 40126941 ↗